Clinical trials: Treated Hypertension
Pre-hypertension
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study…
- Trial name
- DETECT (NCT00553969)
- Testing
- carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Minnesota
Pulmonary Hypertension, Sickle Cell Disease
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects.
- Trial name
- MENSCH (NCT02651272)
- Testing
- macitentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Treated Hypertension
Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention
The primary aim of the pilot study is to provide data that can be used to better determine sample size for the design of a larger clinical trial.
- Trial name
- NCT01780974
- Testing
- Lipoic Acid plus Omega-3 Fatty Acids
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Oregon Health and Science University
Childhood Glaucoma
Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
Objectives: The study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a selected sample of patients affected by primary Pediatric Glaucoma (PG), refractory to surgical procedures.
- Trial name
- NCT01527682
- Testing
- Latanoprost, Dorzolamide
- Where
- 2 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Hypertension
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
The primary objective of this trial is to demonstrate that following eight weeks of treatment the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line therapy in reducing mean seated trough cuff…
- Trial name
- NCT00860262
- Testing
- amlodipine, telmisartan, telmisartan and amlodipine
- Where
- 137 sites in United States, Bulgaria and 9 more
- Volunteers
- 858 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Hemorrhage
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure >160 mmHg) in patients with intracerebral hemorrhage…
- Trial name
- ACCELERATE (NCT00666328)
- Testing
- clevidipine
- Where
- 17 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- The Medicines Company
Open-Angle Glaucoma, Ocular Hypertension
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions.
- Trial name
- NCT04910100
- Testing
- Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Betaliq, Inc.
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension, Public Health; Nursing Staff
Nursing Interventions Based on Protection Motivation Theory in Hypertensive Patients
Hypertension is a major global public health problem. In order to be successful in hypertension management, patients should receive timely and accurate diagnosis, acquire healthy lifestyle habits, start antihypertensive drug…
- Trial name
- NCT05995977
- Testing
- Nursing interventions based on protection motivation theory in patients with hypertension
- Where
- Turkey (Türkiye)
- Volunteers
- 78 people
- Sponsor
- Necmettin Erbakan University
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Hypertension
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
- Trial name
- NCT01420068
- Testing
- SPP100
- Where
- 25 sites in United States, Guatemala and 5 more
- Volunteers
- 106 people
- Sponsor
- LXO Group
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
This is a single center, open-label trial designed to assess the safety and efficacy of ranolazine (Ranexa) in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction.
- Trial name
- NCT02133352
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston University
Glaucoma, Ocular Hypertension
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P)…
- Trial name
- NCT01525173
- Testing
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Arterial Hypertension, Hypertension, Resistant to Conventional Therapy
The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.
- Conditions
- Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus
- Trial name
- SDHDS (NCT01062763)
- Testing
- spironolactone
- Volunteers
- 119 people
- Sponsor
- Ib Abildgaard Jacobsen
Glaucoma, Ocular Hypertension
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02167035
- Testing
- Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Cornerstone Health Care, PA
Hypertension
Uncontrolled Hypertension Among the Homeless
This study is designed to assess the effect of implementing a mobile health (mHealth) strategy using text messaging for hypertension (HTN) management among hypertensive homeless persons with uncontrolled blood pressure age 21 or…
- Trial name
- NCT05187013
- Testing
- mHealth for Hypertension in Homeless Persons
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- George Washington University